comparemela.com

Latest Breaking News On - Regensburg center - Page 1 : comparemela.com

Physicists reach atomic-scale telegraphy with light

Physicists reach atomic-scale telegraphy with light
phys.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phys.org Daily Mail and Mail on Sunday newspapers.

Medigene AG: Medigene achieves positive preliminary results in Phase I of Phase I/II trial of TCR-T therapy MDG1011 in blood cancers

Medigene AG: Medigene achieves positive preliminary results in Phase I of Phase I/II trial of TCR-T therapy MDG1011 in blood cancers Planegg/Martinsried (pta/21.12.2021/15:20) MDG1011 was safe and well tolerated Successful individual manufacturing of MDG1011 drug product from heavily pre-treated patients wi.

Regensburg Center for Interventional Immunology adopts LUMICKS z-Movi® Cell Avidity Analyzer

Regensburg Center for Interventional Immunology adopts LUMICKS z-Movi® Cell Avidity Analyzer

Regensburg Center for Interventional Immunology adopts LUMICKS’ z-Movi® Cell Avidity Analyzer Amsterdam, the Netherlands – May 27, 2021 – In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi® Cell Avidity Analyzer. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of chimeric antigen receptors (CARs) and accelerate the development of new CAR-T therapies. The new instrument has been placed in the lab of Dr. Hinrich Abken, Professor and Chair for Genetic Immunotherapy at Regensburg University. Professor Abken is a pioneer in the design and development of CAR T cells for cancer malignancies. His current work is aimed at improving T cell targeting of cancer cells and at translating these strategies into clinical trials.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.